RNA Therapy

Partner Content

5th Oligonucleotides for CNS Summit

The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism

News

PTC's Huntington study was positive. Why did its stock fall?

In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.

News

Woman pushing man in wheelchair along beachfront as sun sets

Novartis pays $1bn upfront for Huntington's drug from PTC

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.

News

Boehringer targets NASH/MASH with $2bn Ribo alliance

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or

Partner Content

Partner Content

RNA Therapy Improves Vision in Child Blindness-More developm...

10th Annual RNA Therapeutics returns to London

Partner Content

MiNA Therapeutics Chief Scientific Officer to speak at RNA T...

CSO of MiRNA Therapeutics to speak at RNA Therapeutics

5th Oligonucleotides for CNS Summit

PTC's Huntington study was positive. Why did its stock fall?

Novartis pays $1bn upfront for Huntington's drug from PTC

Boehringer targets NASH/MASH with $2bn Ribo alliance

RNA Therapy Improves Vision in Child Blindness-More developm...

MiNA Therapeutics Chief Scientific Officer to speak at RNA T...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

RNA Therapy

Editor's Picks